Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

By E. Chang, J. Wefel, K. Hess, P. Allen, F. Lang, D. Kornguth, R. Arbuckle, J. Swint, A. Shiu, M. Maor and 1 more. The Lancet Oncology, 2009

2,317 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine, Radiation

View Paper: https://www.semanticscholar.org/paper/3ea5b5f28207d63ac2af7e80cf8bbe3b10eed9c1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Milica Miočević
2. R. van de Schoot

Citations in the corpus

• Small Sample Size Solutions (2020, background): “The protective effect on cognition has been demonstrated in a related population of patients with fewer brain tumors (Chang et al., 2009; Yamamoto et al., 2014).”
• Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. (2020, background): “These findings specific to patient-reported overall cognitive symptom burden and preservation of memory and speech meaningfully complement the cognitive preservation findings on objective cognitive tests and the cognition-specific rationale for HA.”
• Radiation-induced brain injury: A review (2012, background): “Chang et al. (2009) documented a detectable cognitive impairment at 4 months after fWBI compared to patients treated with radiosurgery.”
• Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. (2014, methodology): “As a relative comparison, the MD Anderson Cancer Center phase III trial of radiosurgery with or without WBRT for one to three brain metastases used a reliable change index to assess HVLT-R TR deterioration at 4 months as its primary end point.(7) That study observed a 24% rate of 4-month HVLT-R TR d”
• Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer (2012, background): “The majority of adverse events relating to ablative therapy occurred in patients having WBRT. Radiation-induced liver damage was not observed in the patient who received liver SBRT. Grade 3 fatigue was reported in two patients within the 6 months after WBRT, but there were no other documented grade ”